SELLAS Life Sciences Group (NASDAQ:SLS) Trading Up 12.9% – Here’s Why

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s stock price traded up 12.9% during trading on Monday . The stock traded as high as $5.29 and last traded at $5.3760. 4,318,045 shares were traded during trading, a decline of 50% from the average session volume of 8,561,953 shares. The stock had previously closed at $4.76.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on SLS shares. Maxim Group increased their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.00.

SELLAS Life Sciences Group Price Performance

The stock has a market cap of $740.12 million, a PE ratio of -21.02 and a beta of 2.18. The business has a fifty day moving average of $4.45 and a 200-day moving average of $2.90.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, equities research analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Grange Capital LLC boosted its stake in shares of SELLAS Life Sciences Group by 18.5% during the 4th quarter. Grange Capital LLC now owns 16,001 shares of the company’s stock worth $60,000 after acquiring an additional 2,500 shares in the last quarter. Invesco Ltd. increased its stake in shares of SELLAS Life Sciences Group by 6.2% in the 4th quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock valued at $201,000 after purchasing an additional 3,114 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in SELLAS Life Sciences Group by 13.6% in the 4th quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock worth $143,000 after purchasing an additional 4,564 shares during the period. Equitable Holdings Inc. raised its holdings in SELLAS Life Sciences Group by 18.5% in the 4th quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock worth $121,000 after purchasing an additional 5,000 shares during the period. Finally, ProShare Advisors LLC boosted its position in SELLAS Life Sciences Group by 31.5% during the fourth quarter. ProShare Advisors LLC now owns 22,638 shares of the company’s stock worth $85,000 after purchasing an additional 5,417 shares in the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.